Dixon Hubard Feinour & Brown Inc. VA increased its stake in Zoetis Inc. (NYSE:ZTS) by 2.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,265 shares of the company’s stock after buying an additional 330 shares during the period. Dixon Hubard Feinour & Brown Inc. VA’s holdings in Zoetis were worth $765,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in the company. Assetmark Inc. boosted its stake in Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after buying an additional 85 shares during the period. Guardian Life Insurance Co. of America boosted its stake in Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the period. Point72 Asia Hong Kong Ltd bought a new stake in Zoetis during the first quarter valued at approximately $111,000. Advisory Services Network LLC acquired a new position in Zoetis during the first quarter valued at about $112,000. Finally, First Interstate Bank boosted its position in Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock valued at $120,000 after buying an additional 76 shares during the last quarter. Institutional investors and hedge funds own 94.51% of the company’s stock.
Shares of Zoetis Inc. (ZTS) opened at 59.73 on Friday. The firm has a market cap of $29.21 billion, a price-to-earnings ratio of 33.76 and a beta of 1.02. The company’s 50 day moving average price is $62.20 and its 200-day moving average price is $58.00. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $63.85.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The company had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the previous year, the business earned $0.49 EPS. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. Equities analysts expect that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
Several research analysts have issued reports on ZTS shares. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price objective for the company in a research report on Wednesday, May 10th. Jefferies Group LLC increased their price objective on Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. BMO Capital Markets reiterated a “buy” rating and issued a $60.00 price objective on shares of Zoetis in a research report on Thursday, May 4th. Argus reiterated a “buy” rating and issued a $69.00 price objective (up previously from $60.00) on shares of Zoetis in a research report on Tuesday, May 30th. Finally, CL King started coverage on Zoetis in a research report on Friday, May 26th. They issued a “buy” rating and a $71.00 price objective for the company. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $64.78.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
What are top analysts saying about Zoetis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zoetis Inc. and related companies.